Build-A-Bear Workshop has been one of the most recognizable and beloved toy brands in the world since opening in 1997. Sharon Price John, CEO of Build-A-Bear Workshop, spoke with Cheddar News about its plans for the holiday season this year as well as the company's first animated feature film.
Share:
More In Business
Big Business This Week: Is China’s Economy on the Ropes?
Abercrombie is back...but never fear Millennials, you don't have to wear low-rise jeans.
Will Mr. Musk Go to Washington? Joining Trump Could Make Trouble for X
CEO of tastytrade Scott Sheridan weighs in on the possibility of Elon Musk joining Trump’s administration, plus the DOJ’s suit against Ticketmaster.
Teeing Up Change: The 14-Year-Old CEO Revolutionizing Girls' Golf Apparel
Featherie, a line of sustainable and functional golf wear for girls, fills a void in the market, catering to the increasing number of female junior golfers.
The Economic ‘Pain’ Fed Chief Jerome Powell Warned About Is Here
Data shows the economy grew less than expected in the first three months of the year, as consumers became more price conscious and spent less.
Will Live Nation and Ticketmaster Actually Be Broken Up?
The CEO of LiveOne, Rob Ellin, discusses the DOJ's lawsuit against Live Nation and Ticketmaster, how will if affect you and the future of live events. Watch!
The Future of Ether ETFs After That SEC Ruling
CoinShares CEO, Jean-Marie Mognetti, joins Cheddar to discuss what's next for ether ETFs and other cryptocurrency after the SEC surprise ruling.
The Trending, Fastest-Growing Summer Destinations Will Surprise You
From the Vegas strip to breathtaking national parks, we’re obsessed.
Nvidia's Blockbuster Run Is Just Getting Started
Nvidia did a record $26 billion in sales in the latest quarter. And get ready for the stock to keep climbing, because the A.I. boom is just getting started.
Perspective Therapeutics Is Creating New Ways to Fight Cancer
In honor of National Cancer Research Month, Perspective Therapeutics discusses its latest treatment — currently in clinical trials — that targets cancer cells d
